Pramlintide · source year
4 selected, source-linked Pramlintide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
3 represented types.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01841359 at 2026-07-30T19:11:49.725Z. Its registry update date was 2023-06-29, and PeptideScanner's reviewed identity mapping was pramlintide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 14 for the reviewed Pramlintide label family with a published date of 2023-02-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PubMed lists PMID 36704426 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2022-10-29 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗